Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen

DB14428ApprovedInvestigationalVaccinesInactivated Meningococcal Vaccine

Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.

First approval
United States, 2010
Brand names
  • Menveo
  • Penmenvy

Resolves to

Compound
UNIIH2W22AGF1P
Clinical / RWD
RxNorm901507

What you can answer from here — as of April 02, 2025

20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
7Marketed productsAcross 3 countries and 5 labellers
Sign in

Which other approved drugs treat the same conditions as Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In